Fingolimod as a new option for multiple sclerosis: A case report

• Autores: Alfredo Hernández Sánchez, Marta Arteta Jiménez
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 14, Nº. 6, 2012, págs. 438-440
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • We report the case of a woman who was diagnosed with relapsing-remitting multiple sclerosis. Initially, she only received symptomatic treatment, but as her relapses became more frequent, she began disease modifying therapy for multiple sclerosis. Inteferon ß-1a was the first option, but the presence of neutralizing antibodies recommended its withdrawal after a few years. Glatiramer acetate was also forced to be resumed as severe dermatological lesions developed. Fingolimod, a new oral agent approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of multiple sclerosis was chosen as an option